Challenges of using high-dose fractionation radiotherapy in combination therapy
Journal
Frontiers in Oncology
Journal Volume
6
Journal Issue
JUN
Date Issued
2016
Author(s)
Abstract
Radiotherapy is crucial and substantially contributes to multimodal cancer treatment. The combination of conventional fractionation radiotherapy (CFRT) and systemic therapy has been established as the standard treatment for many cancer types. With advances in linear accelerators and image-guided techniques, high-dose fractionation radiotherapy (HFRT) is increasingly introduced in cancer centers. Clinicians are currently integrating HFRT into multimodality treatment. The shift from CFRT to HFRT reveals different effects on the tumor microenvironment and responses,particularly the immune response. Furthermore, the combination of HFRT and drugs yields different results in different types of tumors or using different treatment schemes. We have reviewed clinical trials and preclinical evidence on the combination of HFRT with drugs, such as chemotherapy, targeted therapy, and immune therapy. Notably, HFRT apparently enhances tumor cell killing and antigen presentation, thus providing opportunities and challenges in treating cancer. ? 2016 Yang and Chiang.
Subjects
Chemotherapy; High-dose fractionation radiotherapy; Immunotherapy; Stereotactic ablative body radiation therapy; Target therapy
SDGs
Other Subjects
bevacizumab; cetuximab; erlotinib; gefitinib; temozolomide; antigen presentation; cell killing; chemotherapy; clinical trial (topic); conventional fractionation radiotherapy; high dose fractionation radiotherapy; human; immune response; multimodality cancer therapy; overall survival; preclinical study; radioisotope therapy; Review; systemic therapy
Type
journal article